Karn Anukul, Khaddar Satvik, Agrawal Amit, Kapoor Akhil
Department of Medical Oncology, Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, Uttar Pradesh, India 221005.
Ecancermedicalscience. 2021 Sep 14;15:1287. doi: 10.3332/ecancer.2021.1287. eCollection 2021.
Sinonasal mucosal melanoma is a rare malignancy with limited treatment options and a poor prognosis. They are usually diagnosed at an advanced stage owing to their late and nonspecific clinical presentation. Here we present a case of relapsed refractory unresectable malignant melanoma involving the right nasal cavity managed with Oral Metronomic Chemotherapy (OMCT). A 75-year-old male patient was diagnosed with unresectable malignant melanoma involving the right nasal cavity and showed radiological progression after initial management with four cycles of Dacarbazine. He was then shifted to OMCT (Cyclophosphamide, Celecoxib and Tamoxifen), as immunotherapy could not be given due to financial constraints, on which he showed approximately 40% reduction in tumour size after 6 months. This result can have important clinical implications in resource constrained settings, where the use of immunotherapy is limited by great financial burden.
鼻窦黏膜黑色素瘤是一种罕见的恶性肿瘤，治疗选择有限且预后较差。由于其临床表现出现较晚且不具有特异性，通常在晚期才被诊断出来。在此，我们报告一例复发性难治性不可切除的恶性黑色素瘤累及右侧鼻腔，采用口服节拍化疗（OMCT）进行治疗的病例。一名75岁男性患者被诊断为不可切除的恶性黑色素瘤累及右侧鼻腔，在接受四个周期达卡巴嗪的初始治疗后出现影像学进展。由于经济限制无法给予免疫治疗，随后他转而接受OMCT（环磷酰胺、塞来昔布和他莫昔芬）治疗，6个月后肿瘤大小缩小了约40%。这一结果在资源有限的环境中可能具有重要的临床意义，因为在这种环境下，免疫治疗的使用受到巨大经济负担的限制。
